[HTML][HTML] Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

…, Q Lu, Y Hu, G Luo, K Wang, Y Lu, H Li, S Wang… - The lancet, 2020 - thelancet.com
Background No specific antiviral drug has been proven effective for treatment of patients
with severe coronavirus disease 2019 (COVID-19). Remdesivir (GS-5734), a nucleoside …

[HTML][HTML] A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19

B Cao, Y Wang, D Wen, W Liu, J Wang… - New England journal …, 2020 - Mass Medical Soc
Background No therapeutics have yet been proven effective for the treatment of severe
illness caused by SARS-CoV-2. Methods We conducted a randomized, controlled, open-label …

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

…, L Guo, J Xie, G Wang, R Jiang, Z Gao, Q Jin, J Wang… - The lancet, 2020 - thelancet.com
Background A recent cluster of pneumonia cases in Wuhan, China, was caused by a novel
betacoronavirus, the 2019 novel coronavirus (2019-nCoV). We report the epidemiological, …

RETRACTED: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

…, J Xu, G Wang, Y Wang, J Zhong, C Wang, J Wang… - The Lancet, 2021 - thelancet.com
Background The long-term health consequences of COVID-19 remain largely unclear. The
aim of this study was to describe the long-term health consequences of patients with COVID-…

[HTML][HTML] Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

…, T Yu, R Du, G Fan, Y Liu, Z Liu, J Xiang, Y Wang… - The lancet, 2020 - thelancet.com
Background Since December, 2019, Wuhan, China, has experienced an outbreak of
coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome …

1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study

L Huang, Q Yao, X Gu, Q Wang, L Ren, Y Wang, P Hu… - The lancet, 2021 - thelancet.com
Background The full range of long-term health consequences of COVID-19 in patients who
are discharged from hospital is largely unclear. The aim of our study was to comprehensively …

Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study

…, L Guo, M Liu, Y Wang, D Cui, Y Wang… - The Lancet …, 2022 - thelancet.com
Background With the ongoing COVID-19 pandemic, growing evidence shows that a
considerable proportion of people who have recovered from COVID-19 have long-term effects on …

[HTML][HTML] SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study

…, Y Wang, X Wang, L Huang, L Xu, C Wang… - The Lancet …, 2022 - thelancet.com
Background The memory immune response is crucial for preventing reinfection or reducing
disease severity. However, the robustness and functionality of the humoral and T-cell …

6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

…, J Xu, G Wang, Y Wang, J Zhong, C Wang, J Wang… - The Lancet, 2023 - thelancet.com
Background The long-term health consequences of COVID-19 remain largely unclear. The
aim of this study was to describe the long-term health consequences of patients with COVID-…

Comparison of severity scores for COVID-19 patients with pneumonia: a retrospective study

…, Z Liu, Y Wang, B Song, X Gu, Y Wang… - European …, 2020 - Eur Respiratory Soc
Rapidly progressing hypoxemia and acute respiratory distress syndrome were commonly
observed in patients with severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) …